RxDoctor Payments Data

Helen Scott Bayley

Family · Ellicott City, MDNPI 1316599145

Payments from drug & device makers

$1,021in general payments, 2019–2025

Across 37 payments — averaging $27.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$223
  • Novartis$132
  • Dynavax Technologies Corporation$131
  • Bayer$104
  • AstraZeneca$94
  • Exact Sciences$71
  • plus $266 from 7 others

What the payments were for

  • Food & beverage$1,021100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,021 in reported general payments places this provider in the 70th percentile of 2,843 family providers in Maryland.

See all family providers in Maryland

Medicare billing

Part B allowed, 2024
$10,944
Medicare patients
48
Services billed
149

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol55$39,229
TrulicityDulaglutide23$22,602
VascepaIcosapent Ethyl14$3,930
Albuterol Sulfate HfaAlbuterol Sulfate52$1,471
Memantine Hcl ErMemantine Hcl16$1,056
Atorvastatin Calcium78$668
Nifedipine ErNifedipine41$645
Metoprolol Succinate28$510
Pravastatin Sodium31$444
Pantoprazole Sodium35$398
Lisinopril68$393
Amlodipine Besylate67$385
Rosuvastatin Calcium23$356
Bupropion XlBupropion Hcl12$350
Gabapentin23$297

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$94$39,22955 claims
Lilly USA, LLCTrulicity$52$22,60223 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,843 family providers in Maryland.

Other family in Ellicott City

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →